Evidence map›Paper›PMID 42318540›Full record

ArticleBritish journal of biomedical science2026

Performance of a quality control center supporting national antimicrobial resistance surveillance.

Dong Woo Shin, Hyunji Kim, Jeong Su Park, Kyoung Un Park, Min Hyuk Choi, Dokyun Kim, Seok Hoon Jeong, Hee Jung Kim, Young Ah Kim, Kwangjin Ahn and 9 more

Abstract read
In one paragraph

Article in British journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Dong Woo ShinDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Hyunji KimDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Jeong Su ParkDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Kyoung Un ParkDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Min Hyuk ChoiDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea.
Dokyun KimDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea.
Seok Hoon JeongDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hee Jung KimDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Korea.
Young Ah KimDepartment of Laboratory Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, Republic of Korea.
Kwangjin AhnDepartment of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Young UhDepartment of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Yong Jun KwonDepartment of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Jong Hee ShinDepartment of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Soo Hyun KimDepartment of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Jeong Hwan ShinDepartment of Laboratory Medicine and Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Republic of Korea.
Hee Young KangDivision of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Dong Chan MoonDivision of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Sung Young LeeDivision of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Songmee BaeDivision of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ensuring the reliability, standardization, and international comparability of antimicrobial resistance (AMR) surveillance data critically depends on the implementation of robust quality assurance frameworks. South Korea established the Korea Global Antimicrobial Resistance Surveillance System (Kor-GLASS), supported by a centralized quality control center (QCC). As Kor-GLASS transitioned from Phase II to Phase III, new bacterial species and antimicrobial agents were incorporated, underscoring the need to evaluate whether quality assurance performance could be sustained during system expansion. Materials and Methods: We analyzed interlaboratory proficiency testing (IPT) and external quality assessment (EQA) outcomes generated by the QCC between 2020 and 2024, covering Phases II and III of Kor-GLASS. Clinical isolates were collected at participating hospitals and transferred to organism-specialized analysis centers for standardized antimicrobial susceptibility testing (AST), while the QCC independently oversees data quality through IPT and EQA. IPT was conducted by comparing AST results between analysis centers and the QCC using subsets of routine clinical isolates, with acceptance criteria defined as categorical agreement (CA) ≥90% and major error rates <3%. EQA involved quarterly distribution of pre-characterized strains to participating centers. Additional evaluations addressed the performance of newly introduced ceftazidime-avibactam susceptibility testing and interlaboratory validation for Results: Across the study period, overall CA consistently exceeded 97% in IPT, and no EQA failures observed among participating centers. While major errors during Phase II were primarily attributable to AST reading and near-breakpoint discrepancies, their frequency markedly decreased in Phase III following targeted corrective actions and educational interventions. Susceptibility testing for ceftazidime-avibactam showed high concordance between centers, with rare discrepancies limited to near-breakpoint measurements. Interlaboratory validation confirmed acceptable performance for AST of Discussion: These findings demonstrate that a centralized, QCC-led quality assurance framework can maintain stable and reliable AMR surveillance performance during periods of system expansion. Beyond routine oversight, coordinated quality assurance activities function as an evidence-based evaluation of how standardized laboratory data are generated and validated, reinforcing their essential role in sustaining the credibility and future development of AMR surveillance systems.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialQuality ControlHumansLaboratory Proficiency TestingMicrobial Sensitivity TestsRepublic of KoreaAnti-Bacterial Agentsantimicrobial resistanceantimicrobial susceptibility testingexternal quality assessmentinterlaboratory proficiency testingquality assurance

Identifiers

PMID42318540
PMCPMC13272092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.